Novakand Pharma AB (publ) (STO:NOVKAN)

Sweden · Delayed Price · Currency is SEK

0.0401

-0.0049 (-10.89%)

At close: Mar 27, 2026

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Development and Commercialisation of Medical Products						90.00K	3.22M	358.00K	113.00K
Development and Commercialisation of Medical Products Growth						-97.20%	798.32%	216.81%	-
Total						90.00K	3.22M	358.00K	113.00K
Total Growth						-97.20%	798.32%	216.81%	-

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Sweden						-	147.00K	111.00K	113.00K	308.00K
Sweden Growth						-	32.43%	-1.77%	-63.31%	9.22%
Germany						-	3.07M	247.00K	-	-
Germany Growth						-	1142.51%	-	-	-
Total						-	3.22M	358.00K	113.00K	308.00K
Total Growth						-	798.32%	216.81%	-63.31%	9.22%

Source: S&P Global Market Intelligence.